The DOI matches its Crossref record; 183 of the 183 references it cites were found in a registry or an index.
Modified Vaccinia Virus Ankara
Open accessAbstract
Safety tested Modified Vaccinia virus Ankara (MVA) is licensed as third-generation vaccine against smallpox and serves as a potent vector system for development of new candidate vaccines against infectious diseases and cancer. Historically, MVA was developed by serial tissue culture passage in primary chicken cells of vaccinia virus strain Ankara, and clinically used to avoid the undesirable side effects of conventional smallpox vaccination. Adapted to growth in avian cells MVA lost the ability to replicate in mammalian hosts and lacks many of the genes orthopoxviruses use to conquer their host (cell) environment. As a biologically well-characterized mutant virus, MVA facilitates fundamental research to elucidate the functions of poxvirus host-interaction factors. As extremely safe viral vectors MVA vaccines have been found immunogenic and protective in various preclinical infection models. Multiple recombinant MVA currently undergo clinical testing for vaccination against human immunodeficiency viruses, Mycobacterium tuberculosis or Plasmodium falciparum. The versatility of the MVA vector vaccine platform is readily demonstrated by the swift development of experimental vaccines for immunization against emerging infections such as the Middle East Respiratory Syndrome. Recent advances include promising results from the clinical testing of recombinant MVA-producing antigens of highly pathogenic avian influenza virus H5N1 or Ebola virus. This review summarizes our current knowledge about MVA as a unique strain of vaccinia virus, and discusses the prospects of exploiting this virus as research tool in poxvirus biology or as safe viral vector vaccine to challenge existing and future bottlenecks in vaccinology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Delaloye, J., Roger, T., Steiner-Tardivel, Q.-G., Le Roy, D., Knaup Reymond, M., Akira, S., Petrilli, V., Gomez, C. E., Perdiguero, B., Tschopp, J., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000480 · Cited by 310
RetractedBundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
(2013) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/103.1437-1588 · Cited by 11,796
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line.
Boukamp, P., Petrussevska, R. T., Breitkreutz, D., Hornung, J., Markham, A., & Fusenig, N. E. (1988) · The Journal of cell biology · doi:10.1083/jcb.106.3.761 · Cited by 4,170
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H. W., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A. A., Zaki, A., Fouchier, R. A. M., et al. (2013) · Nature · doi:10.1038/nature12005 · Cited by 2,061 · cited 2×
“amino peptidase dipeptidyl 4 or CD26 as functional receptor of MERSCoV-mediating entry into the cell (Raj et al., 2013).”
BackgroundAirborne Transmission of Influenza A/H5N1 Virus Between Ferrets
Herfst, S., Schrauwen, E. J. A., Linster, M., Chutinimitkul, S., de Wit, E., Munster, V. J., Sorrell, E. M., Bestebroer, T. M., Burke, D. F., Smith, D. J., et al. (2012) · Science · doi:10.1126/science.1213362 · Cited by 1,665
Lanciotti, R. S., Roehrig, J. T., Deubel, V., Smith, J., Parker, M., Steele, K., Crise, B., Volpe, K. E., Crabtree, M. B., Scherret, J. H., et al. (1999) · Science · doi:10.1126/science.286.5448.2333 · Cited by 1,593 · cited 1×
“In 1999, the virus was introduced into the New York City District of Queens, supposedly by an infected mosquito or bird (Lanciotti et al., 1999; Murray et al., 2010; Nash et al., 2001).”
BackgroundEmergence of Zaire Ebola Virus Disease in Guinea
Baize, S., Pannetier, D., Oestereich, L., Rieger, T., Koivogui, L., Magassouba, N., Soropogui, B., Sow, M. S., Keïta, S., De Clerck, H., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404505 · Cited by 1,366
The Outbreak of West Nile Virus Infection in the New York City Area in 1999
Nash, D., Mostashari, F., Fine, A., Miller, J., O'Leary, D., Murray, K., Huang, A., Rosenberg, A., Greenberg, A., Sherman, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106143442401 · Cited by 1,362
Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak
Gire, S. K., Goba, A., Andersen, K. G., Sealfon, R. S. G., Park, D. J., Kanneh, L., Jalloh, S., Momoh, M., Fullah, M., Dudas, G., et al. (2014) · Science · doi:10.1126/science.1259657 · Cited by 1,215
McCollum, A. M., & Damon, I. K. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit703 · Cited by 1,086
Tameris, M. D., Hatherill, M., Landry, B. S., Scriba, T. J., Snowden, M. A., Lockhart, S., Shea, J. E., McClain, J. B., Hussey, G. D., Hanekom, W. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60177-4 · Cited by 1,049
The ankyrin repeat as molecular architecture for protein recognition
Mosavi, L. K., Cammett, T. J., Desrosiers, D. C., & Peng, Z. (2004) · Protein Science · doi:10.1110/ps.03554604 · Cited by 907
The complete DNA sequence of vaccinia virus
Goebel, S. J., Johnson, G. P., Perkus, M. E., Davis, S. W., Winslow, J. P., & Paoletti, E. (1990) · Virology · doi:10.1016/0042-6822(90)90294-2 · Cited by 850
Chakrabarti, S., Brechling, K., & Moss, B. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.12.3403 · Cited by 777
A Toll-like receptor–independent antiviral response induced by double-stranded B-form DNA
Ishii, K. J., Coban, C., Kato, H., Takahashi, K., Torii, Y., Takeshita, F., Ludwig, H., Sutter, G., Suzuki, K., Hemmi, H., et al. (2006) · Nature Immunology · doi:10.1038/ni1282 · Cited by 775
Self-citationMiddle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
Haagmans, B. L., Al Dhahiry, S. H. S., Reusken, C. B. E. M., Raj, V. S., Galiano, M., Myers, R., Godeke, G.-J., Jonges, M., Farag, E., Diab, A., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70690-x · Cited by 671
A decade after SARS: strategies for controlling emerging coronaviruses
Graham, R. L., Donaldson, E. F., & Baric, R. S. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3143 · Cited by 655
Vaccinia virus: a selectable eukaryotic cloning and expression vector.
Mackett, M., Smith, G. L., & Moss, B. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.23.7415 · Cited by 646
Mackett, M., Smith, G. L., & Moss, B. (1984) · Journal of Virology · doi:10.1128/jvi.49.3.857-864.1984 · Cited by 644
Schneider, J., Gilbert, S. C., Blanchard, T. J., Hanke, T., Robson, K. J., Hannan, C. M., Becker, M., Sinden, R., Smith, G. L., & Hill, A. V. S. (1998) · Nature Medicine · doi:10.1038/nm0498-397 · Cited by 644
Nonreplicating vaccinia vector efficiently expresses recombinant genes.
Sutter, G., & Moss, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10847 · Cited by 600
Self-citationMcShane, H., Pathan, A. A., Sander, C. R., Keating, S. M., Gilbert, S. C., Huygen, K., Fletcher, H. A., & Hill, A. V. S. (2004) · Nature Medicine · doi:10.1038/nm1128 · Cited by 570
Sui, J., Li, W., Murakami, A., Tamin, A., Matthews, L. J., Wong, S. K., Moore, M. J., Tallarico, A. S. C., Olurinde, M., Choe, H., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307140101 · Cited by 550
McFadden, G. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1099 · Cited by 523
Antoine, G., Scheiflinger, F., Dorner, F., & Falkner, F. G. (1998) · Virology · doi:10.1006/viro.1998.9123 · Cited by 507
Panicali, D., & Paoletti, E. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.16.4927 · Cited by 497
de Jong, J. C., Claas, E. C. J., Osterhaus, A. D. M. E., Webster, R. G., & Lim, W. L. (1997) · Nature · doi:10.1038/39218 · Cited by 497
Chang, H. W., Watson, J. C., & Jacobs, B. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.4825 · Cited by 483
Alcami, A., & Smith, G. L. (1992) · Cell · doi:10.1016/0092-8674(92)90274-g · Cited by 482
Meyer, H., Sutter, G., & Mayr, A. (1991) · Journal of General Virology · doi:10.1099/0022-1317-72-5-1031 · Cited by 474
Self-citationImmunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox
Earl, P. L., Americo, J. L., Wyatt, L. S., Eller, L. A., Whitbeck, J. C., Cohen, G. H., Eisenberg, R. J., Hartmann, C. J., Jackson, D. L., Kulesh, D. A., et al. (2004) · Nature · doi:10.1038/nature02331 · Cited by 455
Rapid generation of a mouse model for Middle East respiratory syndrome
Zhao, J., Li, K., Wohlford-Lenane, C., Agnihothram, S. S., Fett, C., Zhao, J., Gale, M. J., Baric, R. S., Enjuanes, L., Gallagher, T., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323279111 · Cited by 452
Edghill-Smith, Y., Golding, H., Manischewitz, J., King, L. R., Scott, D., Bray, M., Nalca, A., Hooper, J. W., Whitehouse, C. A., Schmitz, J. E., et al. (2005) · Nature Medicine · doi:10.1038/nm1261 · Cited by 452
Expression of rabies virus glycoprotein from a recombinant vaccinia virus
Kieny, M. P., Lathe, R., Drillien, R., Spehner, D., Skory, S., Schmitt, D., Wiktor, T., Koprowski, H., & Lecocq, J. P. (1984) · Nature · doi:10.1038/312163a0 · Cited by 444
West Nile virus infection and immunity
Suthar, M. S., Diamond, M. S., & Gale Jr, M. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro2950 · Cited by 430
Bisht, H., Roberts, A., Vogel, L., Bukreyev, A., Collins, P. L., Murphy, B. R., Subbarao, K., & Moss, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401939101 · Cited by 420
Structure of vaccinia virus late promoters
Davison, A. J., & Moss, B. (1989) · Journal of Molecular Biology · doi:10.1016/0022-2836(89)90108-3 · Cited by 401
Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1
Berthoud, T. K., Hamill, M., Lillie, P. J., Hwenda, L., Collins, K. A., Ewer, K. J., Milicic, A., Poyntz, H. C., Lambe, T., Fletcher, H. A., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq015 · Cited by 384
Human Infection with MERS Coronavirus after Exposure to Infected Camels, Saudi Arabia, 2013
Memish, Z. A., Cotten, M., Meyer, B., Watson, S. J., Alsahafi, A. J., Al Rabeeah, A. A., Corman, V. M., Sieberg, A., Makhdoom, H. Q., Assiri, A., et al. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2006.140402 · Cited by 365
Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity
Smith, G. L., Benfield, C. T. O., Maluquer de Motes, C., Mazzon, M., Ember, S. W. J., Ferguson, B. J., & Sumner, R. P. (2013) · Journal of General Virology · doi:10.1099/vir.0.055921-0 · Cited by 364
Min, C.-K., Cheon, S., Ha, N.-Y., Sohn, K. M., Kim, Y., Aigerim, A., Shin, H. M., Choi, J.-Y., Inn, K.-S., Kim, J.-H., et al. (2016) · Scientific Reports · doi:10.1038/srep25359 · Cited by 364
Goonetilleke, N. P., McShane, H., Hannan, C. M., Anderson, R. J., Brookes, R. H., & Hill, A. V. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1602 · Cited by 360
Russell, C. A., Fonville, J. M., Brown, A. E. X., Burke, D. F., Smith, D. L., James, S. L., Herfst, S., van Boheemen, S., Linster, M., Schrauwen, E. J., et al. (2012) · Science · doi:10.1126/science.1222526 · Cited by 352
Stanley, D. A., Honko, A. N., Asiedu, C., Trefry, J. C., Lau-Kilby, A. W., Johnson, J. C., Hensley, L., Ammendola, V., Abbate, A., Grazioli, F., et al. (2014) · Nature Medicine · doi:10.1038/nm.3702 · Cited by 350
A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA
Ewer, K., Rampling, T., Venkatraman, N., Bowyer, G., Wright, D., Lambe, T., Imoukhuede, E. B., Payne, R., Fehling, S. K., Strecker, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1411627 · Cited by 348
Blanchard, T. J., Andrea, P., Alcami, A., & Smith, G. L. (1998) · Journal of General Virology · doi:10.1099/0022-1317-79-5-1159 · Cited by 336
Carroll, M. W., & Moss, B. (1997) · Virology · doi:10.1006/viro.1997.8845 · Cited by 331
Poxviruses and the evolution of host range and virulence
Haller, S. L., Peng, C., McFadden, G., & Rothenburg, S. (2014) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2013.10.014 · Cited by 321
Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein
Spriggs, M. K., Hruby, D. E., Maliszewski, C. R., Pickup, D. J., Sims, J. E., Buller, R. M. L., & VanSlyke, J. (1992) · Cell · doi:10.1016/0092-8674(92)90273-f · Cited by 319
Falkner, F. G., & Moss, B. (1988) · Journal of Virology · doi:10.1128/jvi.62.6.1849-1854.1988 · Cited by 316
Antibodies against MERS Coronavirus in Dromedary Camels, Kenya, 1992–2013
Corman, V. M., Jores, J., Meyer, B., Younan, M., Liljander, A., Said, M. Y., Gluecks, I., Lattwein, E., Bosch, B.-J., Drexler, J. F., et al. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2008.140596 · Cited by 312
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
Ewer, K. J., O’Hara, G. A., Duncan, C. J. A., Collins, K. A., Sheehy, S. H., Reyes-Sandoval, A., Goodman, A. L., Edwards, N. J., Elias, S. C., Halstead, F. D., et al. (2013) · Nature Communications · doi:10.1038/ncomms3836 · Cited by 286
Antibodies against MERS Coronavirus in Dromedary Camels, United Arab Emirates, 2003 and 2013
Meyer, B., Müller, M. A., Corman, V. M., Reusken, C. B. E. M., Ritz, D., Godeke, G.-J., Lattwein, E., Kallies, S., Siemens, A., van Beek, J., et al. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2004.131746 · Cited by 268
Smallpox vaccines: targets of protective immunity
Moss, B. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00975.x · Cited by 259
An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels
Haagmans, B. L., van den Brand, J. M. A., Raj, V. S., Volz, A., Wohlsein, P., Smits, S. L., Schipper, D., Bestebroer, T. M., Okba, N., Fux, R., et al. (2016) · Science · doi:10.1126/science.aad1283 · Cited by 259
Self-citationBlockade of Chemokine Activity by a Soluble Chemokine Binding Protein from Vaccinia Virus
Alcamí, A., Symons, J. A., Collins, P. D., Williams, T. J., & Smith, G. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.2.624 · Cited by 252
Hayes, C. G., & Monath, T. P. C. (1989) · Cited by 251
Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans
Lillie, P. J., Berthoud, T. K., Powell, T. J., Lambe, T., Mullarkey, C., Spencer, A. J., Hamill, M., Peng, Y., Blais, M.-E., Duncan, C. J. A., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis327 · Cited by 248
Wyatt, L. S., Earl, P. L., Eller, L. A., & Moss, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401165101 · Cited by 247
Webster, D. P., Dunachie, S., Vuola, J. M., Berthoud, T., Keating, S., Laidlaw, S. M., McConkey, S. J., Poulton, I., Andrews, L., Andersen, R. F., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406381102 · Cited by 242
Oral vaccination of the fox against rabies using a live recombinant vaccinia virus
Blancou, J., Kieny, M. P., Lathe, R., Lecocq, J. P., Pastore, P. P., Soulebot, J. P., & Desmettre, P. (1986) · Nature · doi:10.1038/322373a0 · Cited by 241
Modified Vaccinia Virus Ankara Protects Macaques against Respiratory Challenge with Monkeypox Virus
Stittelaar, K. J., van Amerongen, G., Kondova, I., Kuiken, T., van Lavieren, R. F., Pistoor, F. H. M., Niesters, H. G. M., van Doornum, G., van der Zeijst, B. A. M., Mateo, L., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7845-7851.2005 · Cited by 230
Non‐replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase
Sutter, G., Ohlmann, M., & Erfle, V. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00843-x · Cited by 226
Self-citationSmith, E. J., Marié, I., Prakash, A., Garcı́a-Sastre, A., & Levy, D. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008717200 · Cited by 224
Graham, K. A., Lalani, A. S., Macen, J. L., Ness, T. L., Barry, M., Liu, L.-Y., Lucas, A., Clark-Lewis, I., Moyer, R. W., & Mcfadden, G. (1997) · Virology · doi:10.1006/viro.1996.8423 · Cited by 215
Tapia, M. D., Sow, S. O., Lyke, K. E., Haidara, F. C., Diallo, F., Doumbia, M., Traore, A., Coulibaly, F., Kodio, M., Onwuchekwa, U., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00362-x · Cited by 215
Davies, M. V., Elroy-Stein, O., Jagus, R., Moss, B., & Kaufman, R. J. (1992) · Journal of Virology · doi:10.1128/jvi.66.4.1943-1950.1992 · Cited by 214
Moorthy, V. S., Good, M. F., & Hill, A. V. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15267-1 · Cited by 209
West Nile virus and its emergence in the United States of America
Murray, K. O., Mertens, E., & Desprès, P. (2010) · Veterinary Research · doi:10.1051/vetres/2010039 · Cited by 205
Isolation of MERS Coronavirus from a Dromedary Camel, Qatar, 2014
Raj, V. S., Farag, E. A. B. A., Reusken, C. B. E. M., Lamers, M. M., Pas, S. D., Voermans, J., Smits, S. L., Osterhaus, A. D. M. E., Al-Mawlawi, N., Al-Romaihi, H. E., et al. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2008.140663 · Cited by 197
Chen, Z., Zhang, L., Qin, C., Ba, L., Yi, C. E., Zhang, F., Wei, Q., He, T., Yu, W., Yu, J., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.5.2678-2688.2005 · Cited by 183
Selection of recombinant vaccinia viruses on the basis of plaque formation
Blasco, R., & Moss, B. (1995) · Gene · doi:10.1016/0378-1119(95)00149-z · Cited by 182
Vaccinia virus host range genes
Perkus, M. E., Goebel, S. J., Davis, S. W., Johnson, G. P., Limbach, K., Norton, E. K., & Paoletti, E. (1990) · Virology · doi:10.1016/0042-6822(90)90296-4 · Cited by 180
Xiang, Y., Condit, R. C., Vijaysri, S., Jacobs, B., Williams, B. R. G., & Silverman, R. H. (2002) · Journal of Virology · doi:10.1128/jvi.76.10.5251-5259.2002 · Cited by 177
The Vaccinia Virus K1L Gene Product Inhibits Host NF-κB Activation by Preventing IκBα Degradation
Shisler, J. L., & Jin, X.-L. (2004) · Journal of Virology · doi:10.1128/jvi.78.7.3553-3560.2004 · Cited by 177
Dai, P., Wang, W., Cao, H., Avogadri, F., Dai, L., Drexler, I., Joyce, J. A., Li, X.-D., Chen, Z., Merghoub, T., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003989 · Cited by 172
Jahrling, P. B., Hensley, L. E., Martinez, M. J., LeDuc, J. W., Rubins, K. H., Relman, D. A., & Huggins, J. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405954101 · Cited by 171
Equine vaccine for West Nile virus.
Ng, T., Hathaway, D. K., Jennings, N., Champ, D., Chiang, Y. W., & Chu, H. J. (2003) · PubMed · Cited by 167
The Rational Design of an AIDS Vaccine
Douek, D. C., Kwong, P. D., & Nabel, G. J. (2006) · Cell · doi:10.1016/j.cell.2006.02.005 · Cited by 166
The March Toward Malaria Vaccines
Hoffman, S. L., Vekemans, J., Richie, T. L., & Duffy, P. E. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.09.011 · Cited by 164
Ectromelia virus: the causative agent of mousepox
Esteban, D. J., & Buller, R. M. L. (2005) · Journal of General Virology · doi:10.1099/vir.0.81090-0 · Cited by 161
Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis
Wasilenko, S. T., Stewart, T. L., Meyers, A. F. A., & Barry, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235583100 · Cited by 154
Drexler, I., Staib, C., Kastenmüller, W., Stevanović, S., Schmidt, B., Lemonnier, F. A., Rammensee, H., Busch, D. H., Bernhard, H., Erfle, V., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.262668999 · Cited by 153
Self-citationVolz, A., Kupke, A., Song, F., Jany, S., Fux, R., Shams-Eldin, H., Schmidt, J., Becker, C., Eickmann, M., Becker, S., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00614-15 · Cited by 151
Self-citationA protein particle vaccine containing multiple malaria epitopes
Gilbert, S. C., Plebanski, M., Harris, S. J., Allsopp, C. E. M., Thomas, R., Layton, G. T., & Hill, A. V. S. (1997) · Nature Biotechnology · doi:10.1038/nbt1197-1280 · Cited by 147
Song, F., Fux, R., Provacia, L. B., Volz, A., Eickmann, M., Becker, S., Osterhaus, A. D. M. E., Haagmans, B. L., & Sutter, G. (2013) · Journal of Virology · doi:10.1128/jvi.01672-13 · Cited by 145
Self-citationFrey, S. E., Wald, A., Edupuganti, S., Jackson, L. A., Stapleton, J. T., Sahly, H. M. E., El‐Kamary, S. S., Edwards, K. M., KEYSERLING, H. L., Winokur, P. L., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.06.075 · Cited by 144
Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV
Roederer, M., Keele, B. F., Schmidt, S. D., Mason, R. D., Welles, H. C., Fischer, W., LaBranche, C. C., Foulds, K. E., Louder, M. K., Yang, Z., et al. (2013) · Nature · doi:10.1038/nature12893 · Cited by 144
He, Y., Zhou, Y., Wu, H., Luo, B., Chen, J., Li, W., & Jiang, S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.4050 · Cited by 142
Modified Vaccinia Virus Ankara Induces Toll-Like Receptor-Independent Type I Interferon Responses
Waibler, Z., Anzaghe, M., Ludwig, H., Akira, S., Weiß, S., Sutter, G., & Kalinke, U. (2007) · Journal of Virology · doi:10.1128/jvi.01190-07 · Cited by 141
Self-citationA survey of host range genes in poxvirus genomes
Bratke, K. A., McLysaght, A., & Rothenburg, S. (2012) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2012.12.002 · Cited by 137
Bejon, P., Mwacharo, J. K., Kai, O. K., Mwangi, T., Milligan, P. J., Todryk, S. M., Keating, S. M., Lang, T. A., Lowe, B. S., Gikonyo, C., et al. (2006) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0010029 · Cited by 137
Altenburg, A. F., Kreijtz, J. H. C. M., de Vries, R. D., Song, F., Fux, R., Rimmelzwaan, G. F., Sutter, G., & Volz, A. (2014) · Viruses · doi:10.3390/v6072735 · Cited by 135
Self-citationComparative Assessment of Transmission-Blocking Vaccine Candidates against Plasmodium falciparum
Kapulu, M. C., Da, D. F., Miura, K., Li, Y., Blagborough, A. M., Churcher, T. S., Nikolaeva, D., Williams, A. R., Goodman, A. L., Sangaré, I., et al. (2015) · Scientific Reports · doi:10.1038/srep11193 · Cited by 128
Molecular genetics of vaccinia virus: demonstration of marker rescue.
Nakano, E., Panicali, D., & Paoletti, E. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.5.1593 · Cited by 125
McShane, H., Behboudi, S., Goonetilleke, N. P., Brookes, R. H., & Hill, A. V. S. (2002) · Infection and Immunity · doi:10.1128/iai.70.3.1623-1626.2002 · Cited by 123
Designing cell lines for viral vaccine production: Where do we stand?
Genzel, Y. (2015) · Biotechnology Journal · doi:10.1002/biot.201400388 · Cited by 122
Ondondo, B., Murakoshi, H., Clutton, G., Abdul-Jawad, S., Wee, E. G., Gatanaga, H., Oka, S., McMichael, A. J., Takiguchi, M., Korber, B., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.3 · Cited by 114
McShane, H., & Williams, A. (2013) · Tuberculosis · doi:10.1016/j.tube.2013.11.003 · Cited by 112
Greenberg, R. N., Hurley, M. Y., Dinh, D. V., Mraz‐Gernhard, S., Vera, J. G., von Bredow, D., von Krempelhuber, A., Röesch, S., Virgin, G., Arndtz-Wiedemann, N., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138348 · Cited by 110
Anderson, R. J., Hannan, C. M., Gilbert, S., Laidlaw, S., Sheu, E. G., Korten, S., Sinden, R., Butcher, G., Skinner, M., & Hill, A. (2004) · Journal of Immunology · doi:10.4049/jimmunol.172.5.3094 · Cited by 107
Born, T. L., Smith, D. E., Garka, K. E., Renshaw, B. R., Bertles, J. S., & Sims, J. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004077200 · Cited by 104
Efficiently Editing the Vaccinia Virus Genome by Using the CRISPR-Cas9 System
Yuan, M., Zhang, W., Wang, J., Yaghchi, C. A., Ahmed, J., Chard, L. S., Lemoine, N. R., & Wang, Y. (2015) · Journal of Virology · doi:10.1128/jvi.00339-15 · Cited by 103
Wasilenko, S. T., Banadyga, L., Bond, D., & Barry, M. (2005) · Journal of Virology · doi:10.1128/jvi.79.22.14031-14043.2005 · Cited by 100
Williams, A., Goonetilleke, N. P., McShane, H., Clark, S. O., Hatch, G. J., Gilbert, S. C., & Hill, A. V. S. (2005) · Infection and Immunity · doi:10.1128/iai.73.6.3814-3816.2005 · Cited by 100
Construction and Isolation of Recombinant MVA
Staib, C., Drexler, I., & Sutter, G. (2004) · Humana Press eBooks · doi:10.1385/1-59259-789-0:077 · Cited by 96
Self-citationMoorthy, V., Pinder, M., Reece, W. H. H., Watkins, K., Atabani, S. F., Hannan, C. M., Bojang, K., McAdam, K. P. W. J., Schneider, J., Gilbert, S. C., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/378515 · Cited by 96
Near death experiences: Poxvirus regulation of apoptotic death
Taylor, J. M., & Barry, M. (2005) · Virology · doi:10.1016/j.virol.2005.09.032 · Cited by 95
F-Box-Like Domains are Present in Most Poxvirus Ankyrin Repeat Proteins
Mercer, A. A., Fleming, S. B., & Ueda, N. (2005) · Virus Genes · doi:10.1007/s11262-005-1784-z · Cited by 95
Bender, B. S., Rowe, C. A., Taylor, S. F., et al. (1996) · Journal of Virology · doi:10.1128/jvi.70.9.6418-6424.1996 · Cited by 94
Cottingham, M. G., Andersen, R. F., Spencer, A. J., Saurya, S., Furze, J. M., Hill, A. V. S., & Gilbert, S. C. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001638 · Cited by 93
Waibler, Z., Anzaghe, M., Frenz, T., Schwantes, A., Pöhlmann, C., Ludwig, H., Palomo-Otero, M., Alcamí, A., Sutter, G., & Kalinke, U. (2008) · Journal of Virology · doi:10.1128/jvi.01617-08 · Cited by 92
Self-citationDeletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy
Clark, R. H., Kenyon, J. C., Bartlett, N. W., Tscharke, D. C., & Smith, G. L. (2005) · Journal of General Virology · doi:10.1099/vir.0.81417-0 · Cited by 91
Novel vaccine vectors for HIV-1
Barouch, D. H., & Picker, L. J. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3360 · Cited by 90
Host range deletion mutant of vaccinia virus defective in human cells
Drillien, R., Koehren, F., & Kirn, A. (1981) · Virology · doi:10.1016/0042-6822(81)90351-2 · Cited by 90
Cross host transmission in the emergence of MERS coronavirus
Reusken, C. B. E. M., Raj, V. S., Koopmans, M., & Haagmans, B. L. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.01.004 · Cited by 90
Emerging Targets and Novel Approaches to Ebola Virus Prophylaxis and Treatment
Choi, J. H., & Croyle, M. A. (2013) · BioDrugs · doi:10.1007/s40259-013-0046-1 · Cited by 88
Zoonotic Brazilian Vaccinia virus: From field to therapy
Kroon, E. G., Mota, B. E. F., Abrahão, J. S., da Fonseca, F. G., & Trindade, G. D. S. (2011) · Antiviral Research · doi:10.1016/j.antiviral.2011.08.018 · Cited by 88
Highly Attenuated Poxvirus Vectors
Tartaglia, J., Cox, W. I., Taylor, J., Perkus, M. E., Riviere, M., Meignier, B., & Paoletti, E. (1992) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1992.8.1445 · Cited by 87
Goepfert, P., Elizaga, M. L., Seaton, K. E., Tomaras, G. D., Montefiori, D. C., Sato, A., Hural, J., Rosa, S. C. D., Kalams, S. A., McElrath, M. J., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu003 · Cited by 87
Earl, P. L., Wyatt, L. S., Montefiori, D. C., Bilska, M., Woodward, R. A., Markham, P. D., Malley, J. D., Vogel, T. U., Allen, T. M., Watkins, D. I., et al. (2002) · Virology · doi:10.1006/viro.2001.1345 · Cited by 86
Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence
Ferguson, B. J., Benfield, C. T. O., Ren, H., Lee, V. H., Frazer, G. L., Strnadova, P., Sumner, R. P., & Smith, G. L. (2013) · Journal of General Virology · doi:10.1099/vir.0.054114-0 · Cited by 86
GOLDBLUM, N., Sterk, V. V., & PADERSKI, B. (1954) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a119626 · Cited by 86
Chapter 3 Poxvirus Host Range Genes
Werden, S. J., Rahman, M. M., & McFadden, G. (2008) · Advances in virus research · doi:10.1016/s0065-3527(08)00003-1 · Cited by 84
Postigo, A. A., Cross, J. R., Downward, J., & Way, M. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401853 · Cited by 83
Oie, K. L., & Pickup, D. J. (2001) · Virology · doi:10.1006/viro.2001.1090 · Cited by 82
Coulibaly, S., Brühl, P., Mayrhofer, J., Schmid, K., Gerenčer, M., & Falkner, F. G. (2005) · Virology · doi:10.1016/j.virol.2005.06.043 · Cited by 81
Symons, J. A., Adams, E., Tscharke, D. C., Reading, P. C., Waldmann, H., & Smith, G. L. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-11-2833 · Cited by 79
Kim, J. Y., Song, J. Y., Yoon, Y. K., Choi, S., Song, Y. G., Kim, S.-R., Son, H.-J., Jeong, S.-Y., Choi, J.-H., Kim, K. M., et al. (2015) · Infection and Chemotherapy · doi:10.3947/ic.2015.47.4.278 · Cited by 79
Orthopoxvirus IL-18 Binding Proteins: Affinities and Antagonist Activities
Calderara, S., Xiang, Y., & Moss, B. (2001) · Virology · doi:10.1006/viro.2000.0689 · Cited by 78
Herbert, M., Squire, C. J., & Mercer, A. A. (2015) · Viruses · doi:10.3390/v7020709 · Cited by 77
García‐Arriaza, J., Nájera, J. L., Gómez, C. E., Tewabe, N., Sorzano, C. Ó. S., Calandra, T., Roger, T., & Estéban, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024244 · Cited by 77
Structure and Function of A41, a Vaccinia Virus Chemokine Binding Protein
Bahar, M. W., Kenyon, J. C., Pütz, M. M., Abrescia, N. G. A., Pease, J. E., Wise, E. L., Stuart, D. I., Smith, G. L., & Grimes, J. M. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.0040005 · Cited by 77
Lambe, T., Carey, J. B., Li, Y., Spencer, A. J., van Laarhoven, A., Mullarkey, C. E., Vrdoljak, A., Moore, A., & Gilbert, S. C. (2013) · Scientific Reports · doi:10.1038/srep01443 · Cited by 76
Wyatt, L. S., Earl, P. L., Xiao, W., Americo, J. L., Cotter, C. A., Vogt, J., & Moss, B. (2009) · Journal of Virology · doi:10.1128/jvi.00687-09 · Cited by 75
Kreijtz, J. H. C. M., Suezer, Y., de Mutsert, G., van den Brand, J. M. A., van Amerongen, G., Schnierle, B. S., Kuiken, T., Fouchier, R. A. M., Löwer, J., Osterhaus, A. D. M. E., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/595984 · Cited by 75
Self-citationLiu, J., & McFadden, G. (2014) · Journal of Virology · doi:10.1128/jvi.02262-14 · Cited by 73
The Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies
Rompay, K. K. A. V. (2011) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2011.0234 · Cited by 70
Fischer, S. F., Ludwig, H., Holzapfel, J., Kvansakul, M., Chen, L., Huang, D. C. S., Sutter, G., Knese, M., & Häcker, G. A. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401718 · Cited by 68
Self-citationSivan, G., Ormanoglu, P., Buehler, E. C., Martin, S. E., & Moss, B. (2015) · mBio · doi:10.1128/mbio.01122-15 · Cited by 67
Ebolavirus Evolution: Past and Present
Vega, M.-A. D. L., Stein, D. R., & Kobinger, G. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005221 · Cited by 67
Loubet, P., Lenzi, N., Galtier, F., Vanhems, P., Loulergue, P., Duval, X., Jouneau, S., Postil, D., Ranger‐Rogez, S., Valette, M., et al. (2016) · Journal of Clinical Virology · doi:10.1016/j.jcv.2016.04.005 · Cited by 67
García‐Arriaza, J., Arnáez, P., Gómez, C. E., Sorzano, C. Ó. S., & Estéban, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066894 · Cited by 65
Improving the MVA Vaccine Potential by Deleting the Viral Gene Coding for the IL-18 Binding Protein
Falivene, J., Zajac, M. P. D. M., Pascutti, M. F., Rodríguez, A. M., Maeto, C., Perdiguero, B., Gómez, C. E., Estéban, M., Calamante, G., & Gherardi, M. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032220 · Cited by 59
Iyer, S. S., Gangadhara, S., Victor, B., Gomez, R., Basu, R., Hong, J. J., LaBranche, C. C., Montefiori, D. C., Villinger, F. J., Moss, B., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500083 · Cited by 55
Reverse guanine phosphoribosyltransferase selection of recombinant vaccinia viruses
Isaacs, S. N., Kotwal, G. J., & Moss, B. A. (1990) · Virology · doi:10.1016/0042-6822(90)90367-z · Cited by 53
Hessel, A., Schwendinger, M. G., Holzer, G. W., Orlinger, K. K., Coulibaly, S., Savidis-Dacho, H., Zips, M.-L., Crowe, B. A., Kreil, T. R., Ehrlich, H. J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016247 · Cited by 51
Ludwig, H., Mages, J., Staib, C., Lehmann, M. H., Lang, R., & Sutter, G. (2005) · Journal of Virology · doi:10.1128/jvi.79.4.2584-2596.2005 · Cited by 50
Self-citationMousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies
Parker, S., Siddiqui, A. M., Oberle, C., Hembrador, E., Lanier, R., Painter, G. R., Robertson, A. T., & Buller, R. M. L. (2008) · Virology · doi:10.1016/j.virol.2008.11.015 · Cited by 48
Kamlangdee, A., Kingstad-Bakke, B. A., Anderson, T. K., Goldberg, T. L., & Osorio, J. E. (2014) · Journal of Virology · doi:10.1128/jvi.01532-14 · Cited by 47
Transmission studies resume for avian flu
Fouchier, R. A. M., García‐Sastre, A., Kawaoka, Y., & co-authors, 3. (2013) · Nature · doi:10.1038/nature11858 · Cited by 47
A chemically defined production process for highly attenuated poxviruses
Jordan, I., Northoff, S., Thiele, M., Hartmann, S., Horn, D. M., Höwing, K., Bernhardt, H., Oehmke, S., von Horsten, H., Rebeski, D. E., et al. (2011) · Biologicals · doi:10.1016/j.biologicals.2010.11.005 · Cited by 46
Zitzmann-Roth, E.-M., von Sonnenburg, F., de la Motte, S., Arndtz-Wiedemann, N., von Krempelhuber, A., Uebler, N., Vollmar, J., Virgin, G., & Chaplin, P. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122653 · Cited by 46
Mullarkey, C. E., Boyd, A. C., van Laarhoven, A., Lefèvre, E. A., Carr, B. V., Baratelli, M., Molesti, E., Temperton, N. J., Butter, C., Charleston, B., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201242922 · Cited by 45
Backes, S., Sperling, K. M., Zwilling, J., Gasteiger, G., Ludwig, H., Kremmer, E., Schwantes, A., Staib, C., & Sutter, G. (2009) · Journal of General Virology · doi:10.1099/vir.0.015347-0 · Cited by 45
Self-citationSoluble interferon-γ receptors encoded by poxviruses
Alcamı́, A., & Smith, G. L. (1996) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/0147-9571(96)00013-6 · Cited by 44
HIV-1 vaccines: Challenges and new perspectives
Excler, J., Robb, M. L., & Kim, J. H. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.28462 · Cited by 44
García‐Arriaza, J., Gómez, C. E., Sorzano, C. Ó. S., & Estéban, M. (2014) · Journal of Virology · doi:10.1128/jvi.02723-13 · Cited by 44
Munseri, P., Kroidl, A., Nilsson, C., Joachim, A., Geldmacher, C., Mann, P., Moshiro, C. S., Aboud, S., Lyamuya, E., Maboko, L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119629 · Cited by 43
Ebola: lessons learned and future challenges for Europe
Quaglio, G., Goerens, C., Putoto, G., Rübig, P., Lafaye, P. J., Karapiperis, T., Dario, C., Delaunois, P., & Zachariah, R. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00361-8 · Cited by 43
Nilsson, C., Hejdeman, B., Godoy‐Ramirez, K., Tecleab, T., Scarlatti, G., Bråve, A., Earl, P. L., Stout, R. R., Robb, M. L., Shattock, R. J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131748 · Cited by 41
Kreijtz, J. H. C. M., Suezer, Y., Bodewes, R., Schwantes, A., van Amerongen, G., Verburgh, R. J., de Mutsert, G., van den Brand, J. M. A., Trierum, S. E. V.-V., Kuiken, T., et al. (2010) · Journal of General Virology · doi:10.1099/vir.0.024885-0 · Cited by 40
Self-citationKremer, M., Suezer, Y., Volz, A., Frenz, T., Majzoub, M., Hanschmann, K.-M. O., Lehmann, M. H., Kalinke, U., & Sutter, G. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002557 · Cited by 38
Self-citationSperling, K. M., Schwantes, A., Schnierle, B. S., & Sutter, G. (2008) · Virology · doi:10.1016/j.virol.2008.02.018 · Cited by 36
Self-citationThe Pathogenesis and Immunobiology of Mousepox
Sigal, L. J. (2015) · Advances in immunology · doi:10.1016/bs.ai.2015.10.001 · Cited by 36
Pigs, Poultry, and Pandemic Influenza: How Zoonotic Pathogens Threaten Human Health
Kuiken, T., Fouchier, R. A. M., Rimmelzwaan, G. F., van den Brand, J. M. A., van Riel, D. A. J., & Osterhaus, A. D. M. E. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0204-6_6 · Cited by 35
The influence of delivery vectors on HIV vaccine efficacy
Ondondo, B. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00439 · Cited by 34
Hessel, A., Schwendinger, M. G., Fritz, D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012217 · Cited by 31
Troy, J. D., Hill, H. R., Ewell, M., & Frey, S. E. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.08.032 · Cited by 29
Iyer, S. S., & Amara, R. R. (2014) · Vaccines · doi:10.3390/vaccines2010160 · Cited by 29
Williams, A., James, B. W., Bacon, J., Hatch, K. A., Hatch, G. J., Hall, G. A., & Marsh, P. D. (2004) · Tuberculosis · doi:10.1016/j.tube.2004.11.001 · Cited by 27
New vaccinia virus promoter as a potential candidate for future vaccines
Pilato, M. D., Mejías‐Pérez, E., Gómez, C. E., Perdiguero, B., Sorzano, C. Ó. S., & Estéban, M. (2013) · Journal of General Virology · doi:10.1099/vir.0.057299-0 · Cited by 26
Valentin, A., McKinnon, K. M., Li, J., Rosati, M., Kulkarni, V., Pilkington, G. R., Bear, J., Alicea, C., Vargas‐Inchaustegui, D. A., Patterson, L. J., et al. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.09.005 · Cited by 25
Volz, A., Langenmayer, M. C., Jany, S., Kalinke, U., & Sutter, G. (2014) · Journal of Virology · doi:10.1128/jvi.00945-14 · Cited by 23
Self-citationSperling, K. M., Schwantes, A., Staib, C., Schnierle, B. S., & Sutter, G. (2009) · Journal of Virology · doi:10.1128/jvi.01628-08 · Cited by 21
Self-citationVolz, A., Lim, S. M., Kaserer, M., Lülf, A.-T., Marr, L., Jany, S., Deeg, C. A., Pijlman, G. P., Koraka, P., Osterhaus, A. D. M. E., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.02.042 · Cited by 21
Self-citationHinthong, O., Jin, X.-L., & Shisler, J. L. (2008) · Virology · doi:10.1016/j.virol.2007.11.034 · Cited by 20
Rodríguez, D., González‐Aseguinolaza, G., Rodríguez, J. R., Vijayan, A., Gherardi, M. M., Rueda, P., Casal, J. I., & Estéban, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034445 · Cited by 16
Accelerating HIV-1 Vaccine Efficacy Trials
Barouch, D. H., & Michael, N. L. (2014) · Cell · doi:10.1016/j.cell.2014.10.046 · Cited by 16
Chamcha, V., Kannanganat, S., Gangadhara, S., Nabi, R., Kozlowski, P. A., Montefiori, D. C., LaBranche, C. C., Wrammert, J., Keele, B. F., Balachandran, H., et al. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw034 · Cited by 15
Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines
Meseda, C. A., Atukorale, V. N., Kuhn, J., Schmeisser, F., & Weir, J. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149364 · Cited by 11
Knitlová, J., Hajkova, V., Voska, L., Elsterová, J., Obrova, B., & Mělková, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114374 · Cited by 10
Cited by
The 2022 outbreak and the pathobiology of the monkeypox virus
Kumar, N., Acharya, A., Gendelman, H. E., & Byrareddy, S. N. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102855 · Cited by 511
Human papillomavirus vaccine against cervical cancer: Opportunity and challenge
Wang, R., Pan, W., Jin, L., Huang, W., Li, Y., Wu, D., Gao, C., Ma, D., & Liao, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.039 · Cited by 493
Coronavirus vaccine development: from SARS and MERS to COVID-19
Li, Y.-D., Chi, W.-Y., Su, J.-H., Ferrall, L., Hung, C.-F., & Wu, T.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00695-2 · Cited by 453
Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity
Larsen, M. D., de Graaf, E. L., Sonneveld, M. E., Plomp, H. R., Nouta, J., Hoepel, W., Chen, H.-J., Linty, F., Visser, R., Brinkhaus, M., et al. (2021) · Science · doi:10.1126/science.abc8378 · Cited by 408
The use of viral vectors in vaccine development
Travieso, T., Li, J., Mahesh, S., Mello, J. D. F. R. E., & Blasi, M. (2022) · npj Vaccines · doi:10.1038/s41541-022-00503-y · Cited by 310
Metadata
- Authors
- Volz, A., & Sutter, G.
- Venue
- Advances in Virus Research
- Publisher
- Elsevier
- Published
- 2017
- Volume
- 97
- Pages
- 187-243
- ISSN
- 0065-3527 (ISSN-L)
- OpenAlex
- W2504828590
- Cited by
- 323
- References
- 183
- FWCI
- 62.22
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.